Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 2/20 | 0.30 |
| ▸ | PDE1A | P54750 | 2/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.30 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19362146 | 0.95 | KDM4E (0.40) | KDM4ETAS1R3TAS1R1ALDH1A1MEN1 | |
| SCHEMBL22408780 | 0.88 | TYMP (0.36) | KDM4E | |
| SCHEMBL22408779 | 0.88 | TYMP (0.36) | KDM4E | |
| SCHEMBL19627587 | 0.83 | PDE5A (0.31) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL19627579 | 0.83 | PDE5A (0.31) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL19627588 | 0.83 | PDE5A (0.31) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL19627585 | 0.83 | PDE5A (0.31) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL19604056 | 0.82 | KDM4E (0.44) | KDM4ETAS1R3TAS1R1ALDH1A1MEN1 | |
| SCHEMBL17775275 | 0.81 | P2RY12 (0.39) | ADORA3 | |
| SCHEMBL19627580 | 0.81 | P2RY12 (0.39) | ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814407-B2 | Multiple coupling and oxidation method | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2023-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814407-B2 | Multiple coupling and oxidation method | RNGTT, PCNA, TYMP | KDM4E 2834/4885TAS1R3 4711/4885TAS1R1 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.